Target Product Profile – OncoLiquid ctDNA Assay (Demo)
=====================================================

**Product Summary**
- Program: Oncology Liquid Biopsy Initiative
- Assay Name: OncoLiquid ctDNA Assay
- Therapeutic Area: Solid Tumors
- Phase: Commercial Pilot

**Project Charter Anchors**
- Project Title: OncoLiquid ctDNA Assay Launch
- Executive Sponsor: Dr. Helena Kim, VP Precision Oncology
- Project Manager: Luis Martinez, PMP
- Core Team: Regulatory Affairs, Clinical Operations, Bioinformatics, Commercial Enablement

**Objectives**
1. Launch a CLIA-compliant ctDNA assay targeting metastatic solid tumor indications by Q4.
2. Achieve >95% analytical sensitivity for actionable variants at 0.5% VAF.
3. Secure CPT code alignment and payer coverage for initial markets (US, EU5).

**Scope Summary**
- Included: Assay validation, LIS integration, clinical validation study, market access dossier, commercialization toolkit.
- Excluded: Companion diagnostic submissions, direct-to-patient marketing, home sample collection kits.

**Key Milestones**
- Analytical Validation Complete – July 15
- Clinical Study Enrollment Complete – August 30
- CLIA Audit Clearance – September 20
- Commercial Launch Readiness Review – October 31

**Risks & Mitigations**
- Regulatory delay → Pre-submit package reviewed monthly with FDA liaison.
- Sample quality variability → Implement plasma QC SOPs and retraining for collection sites.
- Bioinformatics pipeline drift → Weekly monitoring with automated alert thresholds and rollback plan.

**Success Metrics**
- 95% positive percent agreement in validation cohort.
- 90% of target oncologists trained before launch.
- Net promoter score ≥ 60 within first quarter of release.

Use this document as the canonical acceptance artifact for intent-only extraction demos and tests.
